Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

oral myeloma therapy

- PMLiVE

Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

A round-up from pharma, biotech and healthcare

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

- PMLiVE

Daily Brief: Andrew Witty’s replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

The latest news from across pharma, biotech and healthcare

- PMLiVE

Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more

Highlights from the world of pharma, biotech and healthcare

- PMLiVE

NICE set to reject Kyowa Kirin’s Crysvita for XLH

Committee says the rare disease therapy isn’t value for money

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

- PMLiVE

Pharma and biotech leaders back ’no deal’ Brexit warning

Ongoing division in Conservative party means 'no deal' remains a possibility

- PMLiVE

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

News from the frontline of healthcare, pharma and biotech

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Daily Brief: Takeda seals $62bn Shire deal, Autolus IPO, Gottlieb warning

A rapid round-up of the top pharma, biotech and healthcare news

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links